Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats

Life Sciences
S TakakuraToshiyuki Takasu

Abstract

We investigated the effect of the selective sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin on the simultaneous progression of diabetic microvascular complications of retinopathy, nephropathy and neuropathy in individual Spontaneously Diabetic Torii (SDT) fatty rats. Ipragliflozin was administered to male SDT fatty rats for 12weeks. Male Sprague-Dawley rats of the same age were used as non-diabetic controls. Non-fasting plasma glucose and glycated hemoglobin levels were measured every 4weeks. Cataract formation was monitored once a week, and the electroretinogram was measured after 6weeks of treatment. After the treatment period, motor nerve conduction velocity was measured and urinalysis was conducted. Tissue samples were then dissected for histopathological examination. Treatment with ipragliflozin reduced glycated hemoglobin levels, inhibited the progression of cataract formation, prevented the prolongation of oscillatory potential peaks in the electroretinogram, ameliorated the slowing of motor nerve conduction velocity, and reduced the severity of glomerulosclerosis in SDT fatty rats. These results suggest that the control of hyperglycemia with ipragliflozin slows the progression of the diabetic complicati...Continue Reading

References

Sep 1, 1974·Journal of the Neurological Sciences·A K Sharma, P K Thomas
Aug 24, 1999·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·C BradleyR Plowright
Aug 31, 1999·Survey of Ophthalmology·R Tzekov, G B Arden
Jan 27, 2004·Biochemical and Biophysical Research Communications·Taku MasuyamaKazuyuki Taniguchi
Mar 29, 2005·Diabetes Care·Andrew J M BoultonUNKNOWN American Diabetes Association
Apr 21, 2005·European Journal of Pharmacology·Hiroaki NakamuraTomihisa Yokoyama
Aug 4, 2007·Kidney International. Supplement·Y J LeeH J Han
Apr 19, 2008·Experimental Animals·Kenichi MatsuiMutsuyoshi Matsushita
Jan 8, 2009·Diabetes, Obesity & Metabolism·Iskandar Idris, Richard Donnelly
Jan 20, 2009·Investigative Ophthalmology & Visual Science·Hille W van DijkMichael D Abràmoff
Feb 20, 2010·Journal of the American Society of Nephrology : JASN·Thijs W Cohen TervaertUNKNOWN Renal Pathology Society
May 29, 2010·Nature Reviews. Drug Discovery·Edward C Chao, Robert R Henry
Jul 10, 2010·Journal of the American Society of Nephrology : JASN·Volker VallonTimo Rieg
Jul 28, 2010·Experimental Animals·Yukihito IshiiTakeshi Ohta
Dec 2, 2010·Clinical Medicine : Journal of the Royal College of Physicians of London·Karunakaran Vithian, Steven Hurel
May 25, 2011·Endocrine Reviews·Muhammad A Abdul-GhaniRalph A Defronzo
Dec 6, 2011·Naunyn-Schmiedeberg's Archives of Pharmacology·Atsuo TaharaMasayuki Shibasaki
Aug 2, 2012·The Journal of Veterinary Medical Science·Takayuki YamaguchiMutsuyoshi Matsushita
Mar 16, 2013·The Journal of Pharmacology and Experimental Therapeutics·Naoki KojimaRichard J Roman
Jan 28, 2014·The Journal of Clinical Investigation·Ele FerranniniHans-Juergen Woerle
Mar 8, 2014·Journal of the American Society of Hypertension : JASH·William L BakerWilliam B White
Apr 29, 2014·Experimental Animals·Yoshiaki KatsudaTakahisa Yamada
Sep 24, 2014·Drug Design, Development and Therapy·Michael A Nauck
Oct 15, 2014·Clinical and Experimental Pharmacology & Physiology·Toshiyuki TakasuShoji Takakura

❮ Previous
Next ❯

Citations

May 2, 2018·Biological & Pharmaceutical Bulletin·Toshiyuki Takasu, Shoji Takakura
Nov 30, 2018·Clinical and Experimental Pharmacology & Physiology·Shoji Takakura, Toshiyuki Takasu
Aug 21, 2018·International Journal of Endocrinology·Lakshini Y HeratMarkus Schlaich
Jan 25, 2017·Pharmacology Research & Perspectives·Keisuke MitsuokaSosuke Miyoshi
Oct 23, 2019·Journal of Diabetes Research·Yoshiaki TanakaAkihiro Kakehashi
Mar 20, 2020·International Journal of Endocrinology·Christopher El MouhayyarSami Azar
Mar 5, 2019·Biological & Pharmaceutical Bulletin·Toshiyuki TakasuShoji Takakura
Jun 19, 2018·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·Ahmed ElgebalyNoha Nasreldin
Dec 5, 2020·Journal of Diabetes Research·Wenjun ShaLigang Zhou
Feb 27, 2021·Cardiovascular Endocrinology & Metabolism·Sejal LahotiRobert Chilton
Aug 30, 2021·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Tushar IssarArun V Krishnan

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.